人民财讯7月18日电,海普瑞(002399)7月18日晚间公告,公司自主研发的创新候选药物注射用H1710(简称“H1710”)I期临床试验已完成首例受试者入组及首次给药。H1710通过抑制乙酰肝素酶的活性和表达,展现出抗肿瘤作用。H1710作为靶向乙酰肝素酶的全新化合物,具有更为合理的链长和独特的柔性结构,是一种高效、高选择性的乙酰肝素酶抑制剂。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.